On October 30th, five domestic pharmaceutical companies received approval for new drugs on ‘a 4:1 w/w mixed gel of sodium hyaluronate gel and sodium hyaluronate solution cross-linked with divinyl sulfone.’
This is the first time in Korea that the drug with this component has been approved for sale.
The products are ▲Hyalsix Inj. (Kwang Dong Pharma) ▲Hyalbonpluswons Inj. (Kyung Dong Pharma) ▲Bonisenwons Inj. (Daewon Pharma) ▲Lesinowon Inj. (YooYoung Pharma) ▲Hyaltanwon Inj. (Jeil Pharma).
These are classified as “new drugs” by the Ministry of Food and Drug Safety and were approved as a treatment for osteoarthritis of the knee.
Osteoarthritis of the knee joint is known to have the highest prevalence among degenerative osteoarthritis that more than 10% of the population suffers.
However, it should not be used in patients with infected or severe inflammation of the joint cavity or skin infections or skin diseases in the area of the injection.
YooYoung Pharmaceutical will be in charge of manufacturing all five products.
